BioInnovation

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company specializes in the development and commercialization of silk biomaterial technologies, particularly the MIMIX microneedle platform, which facilitates transdermal delivery of vaccines and therapeutics. This innovative sustained release patch technology enhances vaccine administration by simulating a natural infection, promoting a robust and prolonged immune response, thereby improving vaccine effectiveness. Additionally, Vaxess’s MATRIX formulation and drying platform creates thermostable vaccines, therapeutics, and diagnostic products that do not require refrigeration, making them suitable for distribution in low-resource settings. Through these advanced solutions, Vaxess aims to improve patient outcomes in oncology care and infectious diseases while reducing treatment burdens for healthcare practitioners.

Cereius, Inc. is a pre-clinical stage biotechnology company based in Durham, North Carolina, focused on developing innovative small-molecule therapies for brain metastasis, particularly in patients with HER2-positive breast cancer. Incorporated in 2017, the company specializes in novel radiolabeling chemistries that enhance the uptake and retention of radionuclides in targeted tumors while reducing the absorption in healthy tissues. This approach significantly improves both the therapeutic index and the diagnostic contrast of targeting agents, enabling medical practitioners to more effectively treat solid tumor brain metastasis and potentially improve patient survival rates.

PanTher Therapeutics, Inc. is a biotechnology company focused on developing innovative drug-delivery treatments for cancer. Founded in 2014 and based in Cambridge, Massachusetts, the company has created a proprietary platform that enhances therapeutic responses while minimizing side effects. This technology allows for direct and sustained delivery of drugs to tumor sites, thereby improving the efficacy of treatment and reducing the toxicity often associated with traditional intravenous or oral administration methods. PanTher's distinctive targeting capability positions it to address some of the most challenging cancer types, with a lead investigational candidate aimed at treating pancreatic cancer.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Avexegen Therapeutics Inc. is a development stage biotechnology company based in San Diego, California, founded in 2014. The company specializes in creating innovative therapies aimed at healing damaged and inflamed gut tissue in patients suffering from gastrointestinal disorders, particularly Crohn's disease and ulcerative colitis. Additionally, Avexegen focuses on addressing needs in premature infants with necrotizing enterocolitis. By employing a novel approach to treatment, Avexegen aims to improve the long-term health outcomes of patients with these serious conditions.

Sentien Biotechnologies, Inc. is a clinical-stage biotechnology company focused on developing innovative cell therapies aimed at restoring immune system balance and improving treatment options for patients with systemic inflammatory diseases. The company specializes in proprietary cell compositions and Good Manufacturing Practice (GMP) manufacturing methods that enhance the efficacy of cell therapy. Its flagship product, SBI-101, utilizes an extracorporeal device to immobilize Mesenchymal Stromal Cells (MSCs), facilitating sustained and controlled delivery of their therapeutic properties, which include anti-inflammatory and regenerative effects. Additionally, the company offers the Sentinel device, designed to treat patients during dialysis by supplementing their blood with MSC-derived secretions that address immune dysfunction and promote tissue repair. Founded in 2008, Sentien Biotechnologies is headquartered in Medford, Massachusetts.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company specializes in the development and commercialization of silk biomaterial technologies, particularly the MIMIX microneedle platform, which facilitates transdermal delivery of vaccines and therapeutics. This innovative sustained release patch technology enhances vaccine administration by simulating a natural infection, promoting a robust and prolonged immune response, thereby improving vaccine effectiveness. Additionally, Vaxess’s MATRIX formulation and drying platform creates thermostable vaccines, therapeutics, and diagnostic products that do not require refrigeration, making them suitable for distribution in low-resource settings. Through these advanced solutions, Vaxess aims to improve patient outcomes in oncology care and infectious diseases while reducing treatment burdens for healthcare practitioners.

Chlorion Pharma is a start-up biotechnology company focused on developing innovative therapeutics for the treatment of pain and epilepsy. The company's approach targets neuronal hyperactivity by correcting aberrant chloride homeostasis, aiming to provide effective solutions for patients suffering from neuropathic diseases. Through its research and development efforts, Chlorion Pharma seeks to address unmet medical needs in the field of neurology, offering the potential for improved therapeutic outcomes for individuals affected by these conditions.

Pegase Medical Inc., a Quebec City-based developer of natural base products for the animal market.